European Equities Traded in US as American Depositary Receipts Surge on Monday

MT Newswires Live01-07 00:16

European equities trading in the US as American depositary receipts were sharply higher late Monday morning, as the S&P Europe Select ADR Index rose 1.6% to 1,315.5.

From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and 3D printer company Materialise (MTLS), which climbed 20% and 6% respectively. They were followed by financial services company Banco Bilbao Vizcaya Argentaria (BBVA) and semiconductor company Sequans Communications (SQNS) that increased almost 5% and 3%, respectively.

The worst decliners in continental Europe were pharmaceutical company Novo Nordisk (NVO) and consumer goods giant Unilever (UL) losing roughly 2% each. They were followed by pharmaceutical company Ascendis Pharma (ASND) and Natuzzi (NTZ), which were down nearly 2% and 1%, respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical company Akari Therapeutics, (AKTX) and alcoholic beverage company Diageo (DEO), gaining 6% and 3%, respectively. They were followed by pharmaceutical company Silence Therapeutics (SLN) and insurance firm Prudential (PUK), which were up 2.6% and 2.9%, respectively.

The worst decliners in the UK and Ireland were biopharmaceutical company TC Biopharm (TCBP) and communications company WPP (WPP), shedding 11% and 2% respectively. They were followed by biotech firm Autolus Therapeutics (AUTL), which dropped 2.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment